Siemens Medical Solutions Usa, Inc.

Eli Lilly and Company

Chul Yu

Kai Chen

Joseph C Walsh

Gang Chen

Umesh B Gangadharmath

Dhanalakshmi Kasi

Anna Katrin Szardenings

Eric Wang

Anjana Sinha

Changhui Liu

Hartmuth C Kolb

Vani P Mocharla

Wei Zhang

Tieming Zhao

Peter J H Scott

Michael Schaefers

Guenter Haufe

Sven Hermann

Andreas Faust

Klaus Kopka

Verena Hugenberg

Stefan Wagner

Hans-Joerg Breyholz

Vani P Mocharia

Daniel Kurt Cashion

Harmuth C Kolb

Peter Jh Scott

Peter JH Scott

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

PSMA imaging agents

Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.

Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof

Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and &#x3b2;-amyloid peptides are presented herein. The invention also relates to methods of imaging A&#x3b2; and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

Imaging agents for detecting neurological disorders

Growing community of inventors

Los Angeles, CA, United States of America

Chul Yu